AKTIS ONCOLOGY INC (AKTS) Fundamental Analysis & Valuation

NASDAQ:AKTS • US01021M1045

Current stock price

18.64 USD
+0.01 (+0.05%)
Last:

This AKTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AKTS Profitability Analysis

1.1 Basic Checks

  • In the past year AKTS has reported negative net income.
  • In the past year AKTS has reported a negative cash flow from operations.
  • In the past 5 years AKTS always reported negative net income.
  • AKTS had negative operating cash flow in 4 of the past 5 years.
AKTS Yearly Net Income VS EBIT VS OCF VS FCFAKTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • AKTS has a Return On Assets of -15.76%. This is in the better half of the industry: AKTS outperforms 78.03% of its industry peers.
  • AKTS has a better Return On Equity (-21.88%) than 80.73% of its industry peers.
Industry RankSector Rank
ROA -15.76%
ROE -21.88%
ROIC N/A
ROA(3y)-26.52%
ROA(5y)-33.1%
ROE(3y)-30.21%
ROE(5y)-43.07%
ROIC(3y)N/A
ROIC(5y)N/A
AKTS Yearly ROA, ROE, ROICAKTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • AKTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTS Yearly Profit, Operating, Gross MarginsAKTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AKTS Health Analysis

2.1 Basic Checks

  • AKTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AKTS remains at a similar level compared to 1 year ago.
  • AKTS has more shares outstanding than it did 5 years ago.
  • AKTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AKTS Yearly Shares OutstandingAKTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AKTS Yearly Total Debt VS Total AssetsAKTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 6.89 indicates that AKTS is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.89, AKTS is in the better half of the industry, outperforming 77.65% of the companies in the same industry.
  • There is no outstanding debt for AKTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.89
ROIC/WACCN/A
WACC9.37%
AKTS Yearly LT Debt VS Equity VS FCFAKTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 9.27 indicates that AKTS has no problem at all paying its short term obligations.
  • AKTS's Current ratio of 9.27 is fine compared to the rest of the industry. AKTS outperforms 78.61% of its industry peers.
  • AKTS has a Quick Ratio of 9.27. This indicates that AKTS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 9.27, AKTS is doing good in the industry, outperforming 78.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.27
Quick Ratio 9.27
AKTS Yearly Current Assets VS Current LiabilitesAKTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AKTS Growth Analysis

3.1 Past

  • The earnings per share for AKTS have decreased strongly by -53.55% in the last year.
  • The Revenue has been growing slightly by 0.64% on average over the past years.
EPS 1Y (TTM)-53.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.21%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-39.21%
Revenue growth 5Y0.64%
Sales Q2Q%-38.39%

3.2 Future

  • The Earnings Per Share is expected to decrease by -32.62% on average over the next years. This is quite bad
  • The Revenue is expected to decrease by -14.91% on average over the next years. This is quite bad
EPS Next Y-357.17%
EPS Next 2Y-34.31%
EPS Next 3Y-32.62%
EPS Next 5YN/A
Revenue Next Year-76.63%
Revenue Next 2Y-24.69%
Revenue Next 3Y-14.91%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AKTS Yearly Revenue VS EstimatesAKTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M 25M
AKTS Yearly EPS VS EstimatesAKTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. AKTS Valuation Analysis

4.1 Price/Earnings Ratio

  • AKTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTS Price Earnings VS Forward Price EarningsAKTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTS Per share dataAKTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • AKTS's earnings are expected to decrease with -32.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.31%
EPS Next 3Y-32.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AKTS Dividend Analysis

5.1 Amount

  • AKTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKTS Fundamentals: All Metrics, Ratios and Statistics

AKTIS ONCOLOGY INC

NASDAQ:AKTS (3/25/2026, 8:10:12 PM)

18.64

+0.01 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)02-11
Inst Owners41.35%
Inst Owner Change-73.62%
Ins Owners0.42%
Ins Owner Change0%
Market Cap944.12M
Revenue(TTM)1.49M
Net Income(TTM)-43.98M
Analysts86
Price Target33.15 (77.84%)
Short Float %2.27%
Short Ratio5.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12900%
PT rev (3m)12900%
EPS NQ rev (1m)-88.56%
EPS NQ rev (3m)-1172.81%
EPS NY rev (1m)-696.25%
EPS NY rev (3m)-696.25%
Revenue NQ rev (1m)-44.38%
Revenue NQ rev (3m)-83.52%
Revenue NY rev (1m)-81.98%
Revenue NY rev (3m)-81.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 634.91
P/FCF N/A
P/OCF N/A
P/B 4.7
P/tB 4.7
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0.03
BVpS3.97
TBVpS3.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.76%
ROE -21.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.52%
ROA(5y)-33.1%
ROE(3y)-30.21%
ROE(5y)-43.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 369.11%
Cap/Sales 515.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.27
Quick Ratio 9.27
Altman-Z 6.89
F-Score3
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)345.4%
Cap/Depr(5y)325.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.21%
EPS Next Y-357.17%
EPS Next 2Y-34.31%
EPS Next 3Y-32.62%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-39.21%
Revenue growth 5Y0.64%
Sales Q2Q%-38.39%
Revenue Next Year-76.63%
Revenue Next 2Y-24.69%
Revenue Next 3Y-14.91%
Revenue Next 5YN/A
EBIT growth 1Y-49.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.93%
EBIT Next 3Y-37.56%
EBIT Next 5YN/A
FCF growth 1Y3.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.38%
OCF growth 3YN/A
OCF growth 5YN/A

AKTIS ONCOLOGY INC / AKTS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AKTIS ONCOLOGY INC (AKTS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to AKTS.


What is the valuation status for AKTS stock?

ChartMill assigns a valuation rating of 0 / 10 to AKTIS ONCOLOGY INC (AKTS). This can be considered as Overvalued.


How profitable is AKTIS ONCOLOGY INC (AKTS) stock?

AKTIS ONCOLOGY INC (AKTS) has a profitability rating of 1 / 10.


What is the financial health of AKTIS ONCOLOGY INC (AKTS) stock?

The financial health rating of AKTIS ONCOLOGY INC (AKTS) is 8 / 10.